Hathal Haddad Highlights Christopher Dürrbeck’s ESTRO-Elekta Award
Hathal Haddad, Head of the Interventional Radiotherapy Unit, Department of Radiation Oncology at University Hospital Tübingen, shared on LinkedIn:
“Congratulations to Christopher Dürrbeck from University Hospital Erlangen on receiving the ESTRO-Elekta Award for his outstanding scientific work:
‘Implant reconstruction in intraoperative prostate HDR brachytherapy: implementation and retrospective evaluation on clinical data.’
This prestigious award, presented by Maarten ter Mors from Elekta during the Breast and prostate brachytherapy session, highlights the impact of innovative research in the field of interventional radiation oncology and the advancement of clinical practice in prostate HDR-BT.
A well-deserved recognition for an excellent contribution to the field!”
This post by Hathal Haddad recognizes Christopher Dürrbeck of University Hospital Erlangen for receiving the ESTRO-Elekta Award at ESTRO 2025. The award was presented during the Breast and Prostate Brachytherapy session by Maarten ter Mors of Elekta, honoring Dürrbeck’s impactful research in high-dose-rate brachytherapy. His study on implant reconstruction during intraoperative prostate HDR procedures represents a significant step toward improving precision and outcomes in interventional radiotherapy. The recognition underscores the growing clinical relevance of Dürrbeck’s work in shaping future standards of care in prostate cancer treatment.
More posts featuring Hathal Haddad.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023